Georgia Medicare Cardiovascular Disease Screening (2026)

Georgia Medicare Cardiovascular Disease Screening covers a cholesterol blood test, the lipid panel, once every five years for asymptomatic Georgia beneficiaries at no out-of-pocket cost. This guide explains the Section 1861(xx) statutory authority, the NCD 190.23 three-test lipid panel, the once-every-five-years frequency, the zero-cost-sharing waiver, how the screening coordinates with the Welcome to Medicare visit and the Annual Wellness Visit, Intensive Behavioral Therapy for Cardiovascular Disease under NCD 210.11, and why the benefit matters in Georgia's Southern Stroke Belt.

Because Medicare treats the screening as a preventive service, the Part B deductible is waived and the standard 20 percent coinsurance does not apply when the provider accepts Medicare assignment, so the beneficiary pays nothing.1

The Federal Statutory Framework for Georgia Medicare Cardiovascular Disease Screening

Section 1861(xx) of the Social Security Act

Section 1861(xx) of the Social Security Act, codified at 42 U.S.C. 1395x(xx), defines the cardiovascular disease screening blood tests covered by Medicare. The statute authorizes Medicare to cover cardiovascular disease screening tests for the early detection of cardiovascular disease (or risk for cardiovascular disease). The statute delegates to CMS authority to:

• Define the specific tests covered
• Establish the screening frequency
• Establish coverage conditions
• Update covered tests as evidence evolves

CMS exercises this delegated authority primarily through National Coverage Determination 190.23 Cardiovascular Disease Screening Tests. Section 1861(xx) was added to the Social Security Act by the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA).

Medicare Improvements for Patients and Providers Act of 2008 (MIPPA)

The Medicare Improvements for Patients and Providers Act of 2008 established Medicare coverage of cardiovascular disease screening blood tests by:

• Adding Section 1861(xx) to the Social Security Act
• Authorizing CMS to specify covered tests and frequency
• Providing for screening of asymptomatic beneficiaries
• Coordinating with the broader Medicare preventive services framework

MIPPA was the same legislation that addressed Medicare physician fee schedule issues, established the Medicare Improvement Fund, and made numerous other Medicare program improvements. The cardiovascular disease screening provision took effect in the years following MIPPA's enactment; verify the current implementing parameters in the CMS Medicare Benefit Policy Manual.

National Coverage Determination NCD 190.23

CMS implemented Section 1861(xx) through National Coverage Determination NCD 190.23 Cardiovascular Disease Screening Tests. NCD 190.23 specifies:

• Covered tests: Total cholesterol, HDL cholesterol, and triglycerides (the standard lipid panel)
• Eligible beneficiaries: All Medicare Part B beneficiaries who are asymptomatic for cardiovascular disease
• Frequency: Once every five years
• Specimen requirements: Fasting blood draw (12-hour fast recommended for accurate triglyceride measurement)
• Provider requirements: Order from a treating physician or other qualified non-physician practitioner

NCD 190.23 has remained substantially stable since its implementation, providing predictable coverage for cardiovascular disease screening tests across the Medicare population.

42 CFR 410.17 Implementing Regulations

Implementing regulations at 42 CFR 410.17 address cardiovascular disease screening tests, including:

• Specific covered tests
• Frequency limitations
• Conditions for coverage
• Documentation requirements

The regulation aligns with NCD 190.23 and provides the regulatory foundation for Medicare contractor claim adjudication.

ACA Section 4104 Preventive Services Cost-Sharing Waiver

Section 4104 of the Patient Protection and Affordable Care Act eliminated Medicare beneficiary cost-sharing for certain preventive services. The cost-sharing waiver applies to preventive services rated A or B by the United States Preventive Services Task Force (USPSTF) and to specific Medicare-defined preventive services, including cardiovascular disease screening tests. Section 4104:

• Waived the Part B deductible for covered preventive services
• Waived the standard 20 percent coinsurance for covered preventive services
• Applied to services furnished beginning in the years following enactment

The result is that Medicare beneficiaries pay nothing out-of-pocket for the cardiovascular disease screening lipid panel covered under Section 1861(xx) when furnished by a Medicare-enrolled provider accepting Medicare assignment. This zero-cost-sharing structure removes financial barriers to preventive cardiovascular screening.1

The Covered Lipid Panel Under Georgia Medicare Cardiovascular Disease Screening

Three-Test Composition

NCD 190.23 specifies the three tests covered under the cardiovascular disease screening benefit:

Total Cholesterol Total cholesterol measures the sum of all cholesterol carried in the blood, including LDL (often called bad) cholesterol, HDL (often called good) cholesterol, and other cholesterol-containing lipoproteins. Total cholesterol provides an overall picture of blood cholesterol but does not distinguish between cardioprotective HDL and atherogenic LDL. Total cholesterol is measured by CPT 82465.

HDL Cholesterol HDL cholesterol (high-density lipoprotein cholesterol) measures the cardioprotective cholesterol that helps remove other cholesterol from arteries. Higher HDL is generally cardioprotective; lower HDL is a cardiovascular risk factor. HDL cholesterol is measured by CPT 83718.

Triglycerides Triglycerides measure the level of triglyceride fats in the blood. Elevated triglycerides are a cardiovascular risk factor and may indicate metabolic syndrome, diabetes, or other metabolic disorders. Triglycerides are measured by CPT 84478.

The Bundled CPT 80061 Lipid Panel Order

Most Medicare cardiovascular disease screening orders use CPT 80061 (Lipid panel), which bundles total cholesterol, HDL cholesterol, and triglycerides into a single laboratory test order. CPT 80061 also typically includes a calculated LDL cholesterol value derived from the other measurements when triglycerides are not severely elevated. The bundled lipid panel is the standard Medicare cardiovascular screening laboratory order.

Fasting Requirements

Accurate triglyceride measurement requires a fasting blood draw, typically 12 hours after the last food or drink intake (water is permitted). Some clinical contexts use non-fasting lipid panels, particularly when only total cholesterol and HDL are of primary interest. Medicare coverage does not require a specific fasting protocol; the clinical decision rests with the ordering provider. Most Georgia Medicare beneficiaries are instructed to schedule morning blood draws after overnight fasting.

Specimen Collection

The screening lipid panel requires a venous blood specimen, typically collected at:

• Primary care provider offices with in-office phlebotomy
• Hospital outpatient laboratories
• Independent laboratory collection sites (Quest Diagnostics, Labcorp)
• Federally Qualified Health Centers (FQHCs)
• Rural Health Clinics (RHCs)
• Community Health Centers

Major commercial laboratories serving Georgia include Quest Diagnostics with patient service centers throughout Georgia, and Labcorp with Georgia collection site coverage. Hospital outpatient laboratories at major Georgia health systems also process screening specimens.

Screening Frequency

Once Every Five Years

Medicare covers cardiovascular disease screening once every five years per beneficiary under NCD 190.23. The frequency limitation:

• Counts from the date of the prior covered screening
• Resets after each covered screening
• Applies regardless of provider, location, or year

A beneficiary screened on March 15, 2026 would be eligible for the next covered screening on or after March 15, 2031. The five-year frequency reflects the relatively slow pace at which lipid profiles change in stable, asymptomatic individuals and the cost-effectiveness considerations of population-wide screening.

What Happens Between Five-Year Intervals

Between covered screening dates, Medicare beneficiaries may have lipid testing under other coverage pathways:

• Diagnostic lipid testing for symptomatic beneficiaries or those with established cardiovascular disease, covered under standard Part B rules with the deductible and 20 percent coinsurance1
• Lipid testing as part of diabetes monitoring, covered under diabetes management
• Lipid testing for statin therapy monitoring, covered as medically necessary
• Lipid testing under risk-stratified clinical pathways, covered as appropriate

The five-year frequency limitation applies only to the preventive cardiovascular disease screening benefit. Beneficiaries needing more frequent lipid testing for clinical reasons can receive it under diagnostic testing rules.

When the Five-Year Clock Starts

The five-year clock starts at the date of the prior Medicare-covered cardiovascular disease screening. For beneficiaries new to Medicare (e.g., newly age 65), the first eligible screening can occur at any point after Medicare Part B enrollment. The IPPE Welcome to Medicare visit (covered within the first 12 months of Part B enrollment) provides a natural entry point for ordering the screening lipid panel.

Asymptomatic Beneficiary Eligibility for Georgia Medicare Cardiovascular Disease Screening

Asymptomatic Defined

The Medicare cardiovascular disease screening benefit applies only to asymptomatic beneficiaries, meaning beneficiaries without signs, symptoms, or established diagnosis of cardiovascular disease. Asymptomatic generally means:

• No chest pain or angina
• No shortness of breath suggestive of heart disease
• No established diagnosis of coronary artery disease, heart failure, peripheral artery disease, cerebrovascular disease, or other cardiovascular disease
• No prior myocardial infarction or stroke

Beneficiaries with cardiovascular disease symptoms or established diagnosis receive lipid testing as diagnostic testing rather than as preventive screening. The clinical distinction rests with the ordering provider's clinical judgment.

Why Asymptomatic-Only

The asymptomatic-only eligibility reflects the preventive nature of the screening benefit. Preventive screening aims to detect disease or risk factors in apparently healthy individuals before symptoms emerge. Once a beneficiary becomes symptomatic or develops established disease, lipid testing serves a diagnostic, monitoring, or treatment-management purpose rather than a screening purpose.

Clinical Coding Implications

For asymptomatic screening eligible for the Section 1861(xx) benefit, the lipid panel is typically coded with ICD-10 Z13.220 (Encounter for screening for lipoid disorders) or similar Z code. For symptomatic or established-disease testing under diagnostic coverage, the lipid panel is coded with the relevant disease ICD-10 (e.g., E78.0 for hypercholesterolemia, I25.10 for atherosclerotic heart disease).

The ICD-10 coding drives Medicare claim processing distinction between screening (cost-sharing waived) and diagnostic (cost-sharing applies). Provider claim coding accuracy is therefore important to ensure beneficiaries receive the appropriate benefit.1

Distinction Between Screening and Diagnostic Testing

Screening Lipid Panel (No Cost-Sharing)

The Section 1861(xx) cardiovascular disease screening benefit applies when:

• The beneficiary is asymptomatic
• The lipid panel is ordered as preventive screening
• The order falls within the once-every-five-years frequency
• The provider codes the encounter with appropriate screening Z codes

Under these conditions, Medicare pays 100 percent of the Medicare-approved amount; the beneficiary pays nothing.1

Diagnostic Lipid Panel (Standard Cost-Sharing)

When the lipid panel is ordered for diagnostic, monitoring, or treatment-management purposes, including:

• Evaluation of symptomatic beneficiaries
• Monitoring of established cardiovascular disease
• Statin therapy initiation, dose titration, or response monitoring
• Diabetes-related lipid monitoring
• Familial hypercholesterolemia evaluation
• Evaluation of other diagnosed lipid disorders

The standard Part B coverage applies: the beneficiary pays the annual Part B deductible ($283 in 2026) if not already met, and after the deductible, 20 percent coinsurance of the Medicare-approved amount.2,1

Practical Implications

In practice, primary care providers managing Medicare beneficiaries often combine the screening lipid panel (when due under five-year frequency) with broader preventive services during the Annual Wellness Visit. For beneficiaries on statin therapy or with established cardiovascular disease, lipid testing typically occurs more frequently than five years under diagnostic coverage with cost-sharing.

Coordination With the Initial Preventive Physical Examination

The Initial Preventive Physical Examination (IPPE), also called the Welcome to Medicare Visit, is codified at Section 1861(ww) of the Social Security Act. It is a one-time preventive visit available within the first 12 months of Medicare Part B enrollment, covering a review of medical and social history, vital signs, depression and cognitive screening, health-risk counseling, and referrals for needed preventive services. It is not a head-to-toe physical exam, but it is the natural entry point for a newly enrolled beneficiary to have the cardiovascular disease screening lipid panel ordered.

During the IPPE, the provider assesses cardiovascular risk factors (family history, diabetes, hypertension, dyslipidemia, smoking, and lifestyle) and may order the screening lipid panel as part of the resulting preventive plan. The IPPE itself is covered at no beneficiary cost-sharing: the Part B deductible and coinsurance are waived. When the screening lipid panel is ordered during or after the IPPE, it too is covered at no cost-sharing, so the visit and the screening together cost the beneficiary nothing.1

Coordination With the Annual Wellness Visit

Section 1861(hhh) AWV

The Annual Wellness Visit (AWV) is codified at Section 1861(hhh) of the Social Security Act. The AWV provides an annual preventive visit available after the IPPE (or after 12 months of Part B enrollment for beneficiaries who did not receive the IPPE). The AWV includes:

• Establishment of (initial AWV) or update to (subsequent AWVs) personalized prevention plan services
• Health Risk Assessment (HRA)
• Review of medical and family history
• List of current providers and prescriptions
• Vital signs measurement
• Cognitive function screening
• Depression screening
• Functional ability and safety screening
• Personalized health advice and referrals
• Screening schedule for next 5-10 years

AWV Cardiovascular Screening Coordination

The AWV personalized prevention plan typically incorporates cardiovascular disease screening when due under the five-year frequency. During each AWV, the provider:

• Reviews the date of the last covered cardiovascular screening
• Determines whether screening is due
• Orders the lipid panel when due
• Counsels on cardiovascular risk factors
• Coordinates with the broader preventive services portfolio (diabetes screening, colorectal cancer screening, cancer screenings, immunizations)

The AWV thus serves as the recurring annual touchpoint for cardiovascular screening management: at each yearly visit the provider checks whether the five-year clock has come due and orders the lipid panel when it has, making the AWV the operational backbone of Medicare preventive cardiovascular care.

AWV and Screening Cost-Sharing

The AWV is covered at no beneficiary cost-sharing under the preventive services waiver, and it is available once every 12 months after a beneficiary has had Part B longer than 12 months. The Part B deductible and coinsurance are waived. When the cardiovascular disease screening lipid panel is ordered during the AWV (or following the AWV with appropriate documentation), the lipid panel is also covered at no cost-sharing. The AWV-plus-screening encounter therefore provides cost-free preventive care for Medicare beneficiaries.1

Coordination With Intensive Behavioral Therapy for Cardiovascular Disease Risk

NCD 210.11 IBT for CVD

National Coverage Determination NCD 210.11 Intensive Behavioral Therapy for Cardiovascular Disease establishes Medicare coverage of intensive behavioral counseling for adults at elevated cardiovascular risk. The benefit:

• Covers one intensive counseling visit per year per beneficiary
• Provides counseling on aspirin use, blood pressure screening, healthy diet, and intensive behavioral counseling
• Must be furnished by a primary care provider in a primary care setting
• Uses HCPCS G0446 (annual face-to-face intensive behavioral therapy for cardiovascular disease, individual)

The IBT for CVD complements the cardiovascular disease screening lipid panel by providing structured counseling and risk reduction interventions in addition to the laboratory screening.

IBT for CVD Cost-Sharing

Like the cardiovascular disease screening benefit, IBT for CVD is covered at no beneficiary cost-sharing under the preventive services waiver. Medicare pays 100 percent of the Medicare-approved amount; the beneficiary pays nothing for the covered annual counseling visit.1

When IBT for CVD Is Most Useful

IBT for CVD is most valuable for beneficiaries with elevated cardiovascular risk based on screening results or other risk factor assessment. Following an abnormal screening lipid panel showing elevated LDL or low HDL, a primary care provider can:

• Discuss results with the beneficiary
• Provide IBT for CVD counseling (G0446)
• Recommend lifestyle modification interventions
• Consider statin therapy when appropriate
• Coordinate other preventive interventions

This sequencing, screening followed by counseling and intervention, exemplifies coordinated preventive cardiovascular care in the Medicare framework.

USPSTF Statin Use Recommendation Alignment

USPSTF Recommendation

The USPSTF provides a recommendation in favor of low- to moderate-dose statin therapy for the primary prevention of cardiovascular disease in adults with cardiovascular risk factors (dyslipidemia, diabetes, hypertension, or smoking) and elevated calculated 10-year cardiovascular disease risk. Consult the current USPSTF recommendation page for the active age band, risk-factor list, and risk threshold.

Implications for Medicare Beneficiaries

While many Medicare beneficiaries are aged 75 or older (beyond the USPSTF primary-prevention age range), the underlying clinical principles of cardiovascular risk reduction inform Medicare preventive care. The cardiovascular disease screening lipid panel provides the data needed to:

• Estimate cardiovascular risk
• Identify beneficiaries who may benefit from statin therapy
• Identify beneficiaries with previously undetected dyslipidemia
• Inform lifestyle counseling and intervention

Statin medications are covered under Medicare Part D for beneficiaries enrolled in Part D plans. Generic statins (atorvastatin, simvastatin, lovastatin, pravastatin, rosuvastatin) are typically available at low cost in Part D plan formularies. The cardiovascular disease screening lipid panel provides the foundation for identifying beneficiaries appropriate for statin consideration.

Service Codes and Documentation

Most Medicare cardiovascular disease screening orders use the bundled CPT 80061 lipid panel, which captures all three required NCD 190.23 components (total cholesterol, HDL cholesterol, and triglycerides) in a single test. The component codes are CPT 82465 (total cholesterol), CPT 83718 (HDL cholesterol), and CPT 84478 (triglycerides); some providers order these separately, but the bundled panel is the standard. CPT 80061 is also the most common diagnostic lipid testing code, so the screening-versus-diagnostic distinction is carried by the accompanying ICD-10 diagnosis code, not the CPT.

To bill the encounter as zero-cost-sharing screening, the ordering provider documents the beneficiary's asymptomatic status, the screening indication, the date of the last covered screening (to confirm the five-year frequency), and a screening ICD-10 code (typically Z13.220, encounter for screening for lipoid disorders). Accurate coding is what drives the claim to adjudicate as screening (zero cost-sharing) rather than diagnostic (cost-sharing applies).

Worked Examples

Example 1: Asymptomatic 67-Year-Old in Macon, Initial Screening Lipid Panel

Mrs. Rodriguez, a 67-year-old Macon resident with no cardiovascular disease symptoms or established diagnosis, visits her primary care provider for her Annual Wellness Visit. During the AWV, the provider reviews her preventive services and notes she has not had a cardiovascular disease screening lipid panel during her Medicare enrollment.

The provider orders CPT 80061 lipid panel with ICD-10 Z13.220 (Encounter for screening for lipoid disorders) at the on-site phlebotomy. The specimen is processed by a commercial laboratory. Results return showing borderline elevated total cholesterol and LDL.

Coverage: The lipid panel is covered under Section 1861(xx) at zero beneficiary cost-sharing because Mrs. Rodriguez is asymptomatic, the screening is within the five-year frequency (first eligible screening), and the order codes the encounter as screening. Mrs. Rodriguez owes nothing for the lipid panel or the AWV during which it was ordered.1

Follow-up: The provider discusses the borderline elevated total cholesterol and LDL with Mrs. Rodriguez. The provider provides IBT for CVD counseling (HCPCS G0446) during the same visit at zero cost-sharing. The counseling addresses dietary modification, physical activity, and weight management. The provider sets a follow-up visit in three months to reassess.

Example 2: Symptomatic Patient, Diagnostic Testing Pathway Versus Screening

Ms. Carter, a 68-year-old Savannah resident with a recent episode of exertional chest pain, presents for evaluation. The cardiologist orders an evaluation, including a lipid panel as part of the diagnostic cardiovascular workup.

Coverage Pathway: Because Ms. Carter is symptomatic (exertional chest pain), the lipid panel is ordered as diagnostic testing rather than as preventive screening. The order uses ICD-10 R07.9 (Chest pain, unspecified) or other diagnostic codes rather than screening Z codes.

Cost-Sharing: The diagnostic lipid panel is covered under standard Part B rules. Ms. Carter pays the Part B deductible if not already met, and after deductible, 20 percent coinsurance of the Medicare-approved amount.

Implication: The cardiovascular disease screening benefit applies to asymptomatic beneficiaries only. Symptomatic beneficiaries access lipid testing under diagnostic coverage with standard cost-sharing.

Example 3: Rural Southwest Georgia Stroke Belt Beneficiary

Mr. Thompson, a 73-year-old resident of Bainbridge in Decatur County (rural southwest Georgia, part of the deep Stroke Belt), receives care at a Federally Qualified Health Center (FQHC). The FQHC primary care provider conducts his Annual Wellness Visit and notes elevated cardiovascular disease risk given:

• Geographic location in the high-burden Stroke Belt region
• Family history (father had myocardial infarction in late 60s)
• Personal history of borderline hypertension
• Age in the elevated-risk Medicare cohort

Screening Order: The FQHC provider orders CPT 80061 lipid panel with ICD-10 Z13.220 at the FQHC on-site phlebotomy. Specimen processing returns results showing elevated LDL.

Coverage: The screening lipid panel is covered at zero beneficiary cost-sharing under Section 1861(xx) and the ACA preventive services waiver. The FQHC primary care setting fully qualifies for the screening benefit.

Follow-up Care: The provider discusses the elevated LDL and initiates IBT for CVD counseling (G0446) during the same visit. The counseling addresses lifestyle modifications appropriate to rural southwest Georgia context (local food access, walking and physical activity options, smoking cessation resources). A follow-up visit in three months is scheduled to reassess and consider statin therapy.

Rural Access Significance: The Section 1861(xx) cardiovascular disease screening benefit is particularly valuable for Mr. Thompson and other rural southwest Georgia Medicare beneficiaries because:

• The Stroke Belt geographic burden elevates baseline cardiovascular risk
• Local FQHCs and Rural Health Clinics provide accessible primary care entry points
• The zero-cost-sharing structure removes financial barriers in lower-income rural communities
• Coordinated AWV plus screening plus IBT for CVD encounters efficiently use scarce rural primary care capacity

Georgia Cardiovascular Disease Burden and Why Georgia Medicare Cardiovascular Disease Screening Matters

Southern Stroke Belt Context

Georgia sits within the Southern Stroke Belt, a region of southern U.S. states historically documented as having elevated stroke mortality compared to national averages. Within Georgia, the cardiovascular and stroke burden is geographically concentrated in:

• Southwest Georgia (Albany, Bainbridge, Thomasville, Valdosta region)
• Coastal Georgia (Savannah, Brunswick region)
• Central Georgia (Macon, Augusta region in part)
• Rural eastern Georgia

The elevated burden reflects multiple contributing factors, including socioeconomic conditions, food environment, healthcare access, tobacco use prevalence, hypertension prevalence, diabetes prevalence, and historical patterns of health disparities.

Why Cardiovascular Screening Matters for Georgia

The Section 1861(xx) cardiovascular disease screening benefit is particularly important for Georgia Medicare beneficiaries because:

• Higher baseline cardiovascular risk warrants systematic screening
• Many beneficiaries have never had structured cholesterol assessment
• Identification of dyslipidemia enables intervention (statin therapy, lifestyle modification)
• Coordination with diabetes screening, blood pressure management, and smoking cessation creates comprehensive cardiovascular risk reduction
• Zero-cost-sharing removes financial barriers in lower-income communities

Georgia Disease Burden Context

Georgia consistently ranks among states with elevated burden for:

• Stroke mortality
• Cardiovascular disease mortality
• Hypertension prevalence
• Diabetes prevalence
• Obesity prevalence

These elevated burden indicators reinforce the value of the Medicare cardiovascular disease screening benefit for the Georgia Medicare population. Consult the Georgia Department of Public Health and CDC state-level cardiovascular surveillance pages for the current data tables.

Major Georgia Cardiovascular Centers

Most Georgia Medicare beneficiaries get their screening lipid panel ordered by their own primary care provider, but abnormal results may lead to a referral to a regional cardiovascular center. Metropolitan Atlanta is served by academic and health-system heart programs including Emory Heart and Vascular Institute, Piedmont Heart Institute, Wellstar Heart and Vascular (metro Atlanta and north Georgia), Northside Cardiovascular, and the Grady Health System safety-net.

Outside Atlanta, regional referral centers include Augusta University Heart and Cardiovascular Services and University Health System in east Georgia, Phoebe Putney Heart Center in Albany (the tertiary center for the deep Stroke Belt of southwest Georgia), and Memorial Health and St. Joseph's/Candler in Savannah for coastal and southeast Georgia. Each of these systems delivers routine cardiovascular screening through its affiliated primary care practices and accepts specialty referrals after an abnormal screen.

Provider Settings for Cardiovascular Disease Screening

Primary Care Provider Offices

Most Medicare cardiovascular disease screening orders originate from primary care provider offices: internal medicine, family medicine, and geriatrics practices. Primary care providers:

• Conduct AWVs incorporating cardiovascular screening
• Order screening lipid panels at on-site phlebotomy or through laboratory referral
• Counsel on cardiovascular risk and intervention
• Coordinate broader preventive care

Primary care is the optimal setting for systematic preventive cardiovascular care for the Medicare population.

Federally Qualified Health Centers (FQHCs)

Federally Qualified Health Centers throughout Georgia provide primary care, including cardiovascular disease screening for Medicare beneficiaries. FQHCs operate under HRSA federal funding and serve underserved communities, including many rural Georgia counties. FQHC services include AWV, cardiovascular screening, and care coordination.

Rural Health Clinics (RHCs)

Rural Health Clinics designated in HRSA Health Professional Shortage Areas or Medically Underserved Areas provide primary care, including cardiovascular disease screening in rural Georgia. RHC services include AWV, cardiovascular screening, and care coordination similar to FQHCs.

Hospital Outpatient Clinics

Hospital outpatient primary care clinics affiliated with major Georgia health systems also provide cardiovascular disease screening for Medicare beneficiaries who receive primary care in these settings.

Independent Laboratory Patient Service Centers

Once a primary care provider orders the screening lipid panel, beneficiaries can have specimen collection at:

• Provider office on-site phlebotomy
• Quest Diagnostics patient service centers throughout Georgia
• Labcorp patient service centers throughout Georgia
• Hospital outpatient laboratory collection sites
• FQHC and RHC on-site phlebotomy

Multiple convenient collection options support accessible screening across urban, suburban, and rural Georgia communities.

Coordination With Other Preventive Screening

Diabetes Screening (Section 1861(yy))

Medicare diabetes screening is codified at Section 1861(yy) of the Social Security Act. The benefit covers diabetes screening tests, including fasting plasma glucose, oral glucose tolerance testing, or HbA1c. The screening benefit is available based on risk factor assessment. Like cardiovascular disease screening, diabetes screening is covered at zero beneficiary cost-sharing under the preventive services waiver.1

The cardiovascular disease screening lipid panel and diabetes screening are commonly ordered together because:

• Both address related metabolic and cardiovascular risk
• Both can be obtained from a single fasting blood draw
• Both inform comprehensive cardiometabolic risk assessment
• Both support coordinated preventive care planning

Other Preventive Screenings Coordinated at the AWV

The Annual Wellness Visit is the natural place to coordinate cardiovascular screening with the rest of Medicare's zero-cost preventive portfolio: colorectal cancer screening (fecal immunochemical test, stool DNA, or screening colonoscopy), the cancer screenings (lung low-dose CT, mammography, cervical cancer screening, and the prostate PSA test), bone mass measurement (DEXA), and abdominal aortic aneurysm screening for eligible beneficiaries. Bundling these at one visit is efficient and keeps each on its own covered schedule.

Diagnostic Testing Pathway

Standard Part B Coverage

When lipid testing is ordered for diagnostic, monitoring, or treatment-management purposes rather than for asymptomatic screening, Medicare Part B covers the testing under standard Part B rules:

• Part B deductible applies ($283 in 2026)2
• After deductible, beneficiary pays 20 percent coinsurance of Medicare-approved amount
• Medicare pays 80 percent of Medicare-approved amount
• Provider must accept assignment for protected pricing1

Common Diagnostic Indications and Frequency

Diagnostic lipid testing is ordered to evaluate cardiovascular symptoms such as chest pain, to monitor established cardiovascular disease, to manage statin therapy (baseline, a few weeks after initiation, then periodically), and to evaluate diabetes-related lipid concerns, familial hypercholesterolemia, or severe hypertriglyceridemia. Unlike the screening benefit, diagnostic testing frequency is set by clinical necessity, not the five-year clock, so a beneficiary who needs more frequent lipid panels for a genuine medical reason can receive them under standard Part B cost-sharing.

Provider Education and Documentation

The cardiovascular disease screening benefit is often underused because providers may be unaware of the five-year frequency, unsure about the asymptomatic-only eligibility rule, or tripped up by the screening-versus-diagnostic coding distinction. EMR-embedded reminders keyed to the last screening date, and standardized screening order templates using CPT 80061 with a screening Z code (Z13.220), close most of that gap. Best provider practices for cardiovascular screening include:

1. Systematic AWV implementation: Use Annual Wellness Visits as the recurring touchpoint for screening management, with EMR-based tracking of the last screening date and the next eligible date.
2. Bundled fasting orders: Coordinate cardiovascular screening with diabetes screening for efficient single-fast specimen collection.
3. Coding accuracy: Use appropriate screening Z codes so the claim adjudicates as zero-cost-sharing screening rather than diagnostic testing.
4. Result-based intervention: Coordinate IBT for CVD (G0446) counseling and statin consideration following abnormal results.
5. Beneficiary education: Explain the zero-cost-sharing structure (the deductible and 20 percent coinsurance are both waived for the screening) to remove perceived barriers, and capture family cardiovascular history for risk stratification.1
6. Follow-up tracking: Ensure abnormal results lead to appropriate follow-up and cardiology referral when warranted.

Common Issues and Resolutions

1. Beneficiary charged cost-sharing for covered screening: Occurs when claim is coded with diagnostic ICD-10 rather than screening Z code. Resolution: provider claim correction with appropriate Z code.
2. Screening ordered too soon (within five years): Frequency violation results in claim denial. Resolution: verify last screening date before ordering; if clinically necessary, order under diagnostic testing rules.
3. Symptomatic patient screening misclassification: Symptomatic patients cannot receive the screening benefit. Resolution: order under diagnostic coverage with appropriate ICD-10 coding.
4. Provider unaware of zero cost-sharing: Some providers incorrectly counsel beneficiaries about cost-sharing for screening. Resolution: provider education on the preventive services cost-sharing waiver.1
5. Beneficiary doesn't fast adequately: Inadequate fasting affects triglyceride accuracy. Resolution: clear pre-test instructions for fasting; reschedule if needed.
6. EMR doesn't flag five-year eligibility: Without EMR support, providers may miss screening opportunities. Resolution: implement EMR reminder systems for cardiovascular screening eligibility.
7. Rural beneficiary access barriers: Specimen collection access can be limited rurally. Resolution: use a Rural Health Clinic, FQHC, mobile phlebotomy, or pharmacy-based collection.

A few more common questions:

Do I need a doctor's order? Yes, the screening lipid panel requires an order from a treating physician or other qualified non-physician practitioner. Primary care providers typically order the screening during the AWV, IPPE, or a routine preventive encounter.

What if I'm in Medicare Advantage (Part C)? Medicare Advantage plans must cover the same preventive services as Original Medicare at zero cost-sharing for in-network providers, so Medicare Advantage beneficiaries access cardiovascular disease screening through their plan's network under the same Section 1861(xx) framework.

Are statins covered? Yes, statin medications are covered under Medicare Part D for beneficiaries enrolled in Part D plans. Generic statins (atorvastatin, simvastatin, lovastatin, pravastatin, rosuvastatin) are typically available at low cost in Part D plan formularies.

Georgia Medicare Cardiovascular Disease Screening: Where to Get Help

If you want to confirm whether your screening is covered at no cost or find help scheduling it, start with GeorgiaCares, Georgia's State Health Insurance Assistance Program, which offers free, unbiased Medicare counseling to beneficiaries and their families. Verify each phone number on the organization's official page before you call. 3

Learn More

Find personalized help navigating Georgia Medicare cardiovascular disease screening at brevy.com.

The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.